OncoCyte Corporation

NASDAQ
OCX
Stock
Yield per half year: +36.48%
Dividend yield: 0%
Sector: Healthcare

Share chart OncoCyte Corporation

Extended chart Simple chart
Financial Markets by TradingView

About OncoCyte Corporation

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

more details
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Grade

Underestimation
Title Value Grade
P/S 16.54 1
P/BV -2.53 0
P/E 0 0
EV/EBITDA -0.4429 0
Total: 3.63
Efficiency
Title Value Grade
ROA, % -110.32 0
ROE, % -910.86 0
Total: 1.67
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0621 10
Total: 10
Growth impulse
Title Value Grade
Yield Revenue, % 56.75 7
Yield Ebitda, % 63.48 8
Yield EPS, % -49.22 0
Total: 5
More

Main owners

Institutions Volume Share, %
Broadwood Capital, Inc. 2 509 066 30.37
AWM Investment Company, Inc. 754 286 9.13
PURA VIDA INVESTMENTS, LLC 586 930 7.11
Vanguard Group Inc 247 873 3
Morgan Stanley 122 973 1.49
Defender Capital, LLC 71 650 0.87
Geode Capital Management, LLC 61 482 0.74
Blackrock Inc. 60 187 0.73
State Street Corporation 16 289 0.2
Renaissance Technologies, LLC 12 718 0.15

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Joshua Riggs President, CEO & Director 504.63k 1983 (42 years)
Mr. James Liu Senior Director, Controller & Principal Accounting Officer 259.83k 1996 (29 years)
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer 409.27k
Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer N/A
Dr. Michael D. West Ph.D. Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. N/A 1953 (72 years)
Mr. Peter Hong VP, General Counsel & Secretary N/A
Ms. Andrea Susan James Chief Financial Officer
Ms. Sandra O'Donald Senior Vice President of Business Operations

About company

Address: United States, Irvine. CA, 15 Cushing - Open in google maps, Open in yandex maps
Website: https://oncocyte.com